热门资讯> 正文
Anavex生命科学公司宣布了自闭症谱系障碍和阿尔茨海默病之间共同生物学的新发现
2026-04-14 19:34
- Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.
- Epidemiological data show that autistic adults may be diagnosed with Alzheimer's and related dementias at rates up to 8 times higher than the general population, with onset occurring years or decades earlier than typical.
- Converging human genetic evidence links numerous high-confidence ASD risk genes — including TSC1/TSC2, PTEN, SHANK3, and FMRP — to impaired cellular autophagy, establishing autophagy dysfunction as a shared molecular substrate across genetically diverse forms of ASD.
- Synaptic dysfunction in ASD is now understood to arise, in substantial part, from a failure of autophagy-dependent synaptic pruning — causing an excess of poorly regulated synaptic connections and disrupted excitatory–inhibitory balance in neural circuits.
- The brain's extracellular matrix (ECM) is pathologically altered in ASD and is bidirectionally coupled to autophagy.
- Restoration of autophagy impairment, now emerging as a central shared pathway in both ASD and AD, is precisely the biological system targeted by blarcamesine through its activation of SIGMAR1.
- Blarcamesine has demonstrated restoration of autophagy through SIGMAR1 activation in preclinical models and has shown clinical effects in Phase IIb/III trials in early Alzheimer's disease, Phase II/III in Rett syndrome (a neurodevelopmental disorder caused by MECP2 mutation), and Phase II in Parkinson's disease dementia.
- Collectively, these data provide a scientific basis for advancing blarcamesine into pivotal clinical studies, subject to further evaluation and regulatory considerations.
推荐文章
港股周报 | 科指再跌破5000点！腾讯创近一年新低！马化腾表示上了AI的船后发现“漏水了”
一周财经日历 | 英伟达、沃尔玛、百度等下周齐放榜！新主席沃什上任后首份美联储会议纪要将出炉
美股机会日报｜通胀压力爆表+美拒绝伊朗停战方案，三大期指齐跌，油价一度飙涨3%；“木头姐”最新持仓出炉！再度减持特斯拉、押注太空概念
一周IPO | 中签即“吃肉”！乐动机器人、剂泰科技上市首日均涨超120%；翼菲科技孖展认购近1.49万倍，成港股新“超购王”
上市首日大涨68%！“英伟达挑战者”Cerebras创下2019年来美国科技公司最大IPO记录！（附投资分析）
特朗普第一季度进行3,642笔股票交易，打破数十年保密信托惯例
时隔九年再访华！特朗普携最强商业天团随行，美股半导体、存储、航空等七大板块或迎来利好
AI算力革命下半场，黄仁勋大笔押注光纤！港美股光通信主线行情爆发，哪些重点标的值得关注？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
